{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:07:45Z","timestamp":1767143265962,"version":"build-2238731810"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s43441-025-00836-5","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:49:39Z","timestamp":1754401779000},"page":"1526-1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies"],"prefix":"10.1007","volume":"59","author":[{"given":"Li-An","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek A","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjeeta","family":"Sinvhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melvin","family":"Munsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"6","key":"836_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/joim.12159","volume":"275","author":"G Trifir\u00f2","year":"2014","unstructured":"Trifir\u00f2 G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551\u201361. https:\/\/doi.org\/10.1111\/joim.12159","journal-title":"J Intern Med"},{"issue":"10","key":"836_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pds.3477","volume":"22","author":"F Xue","year":"2013","unstructured":"Xue F, Ma H, Stehman-Breen C, et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf. 2013;22(10):1107\u201314. https:\/\/doi.org\/10.1002\/pds.3477","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"836_CR3","unstructured":"US Department of Health and Human Services Food and Drug Administration. Prolia US Approval Letter. 2010. Accessed October 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125320s000Approv.pdf"},{"key":"836_CR4","unstructured":"US Department of Health and Human Services Food and Drug Administration. Prolia US Label. 2024. Accessed October 16, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125320s213lbl.pdf"},{"issue":"2","key":"836_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2017.3644","volume":"75","author":"KF Huybrechts","year":"2018","unstructured":"Huybrechts KF, Br\u00f6ms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: A cohort study from the international pregnancy safety study consortium. JAMA Psychiatry. 2018;75(2):167. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3644","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"836_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40264-021-01095-7","volume":"44","author":"V Hoffman","year":"2021","unstructured":"Hoffman V, Hallas J, Linder M, et al. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a Non-Interventional, multinational, cohort study. Drug Saf. 2021;44(8):899\u2013915. https:\/\/doi.org\/10.1007\/s40264-021-01095-7","journal-title":"Drug Saf"},{"key":"836_CR7","unstructured":"US Department of Health and Human Services Food and Drug Administration. sNDA 204629 and 20611: FDA Briefing Information. 2016. Accessed October 16, 2024. https:\/\/wayback.archive-it.org\/7993\/20201227021610\/https:\/\/www.fda.gov\/media\/98910\/download"},{"issue":"3","key":"836_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on Sodium-Glucose Cotransporter-2 inhibitors versus other Glucose-Lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of Sodium-Glucose Cotransporter-2 inhibitors). Circulation. 2017;136(3):249\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029190","journal-title":"Circulation"},{"issue":"2","key":"836_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cpt.1833","volume":"108","author":"R Gini","year":"2020","unstructured":"Gini R, Sturkenboom MCJ, Sultana J, et al. Different strategies to execute Multi-Database studies for medicines surveillance in Real\u2010World setting: A reflection on the European model. Clin Pharmacol Ther. 2020;108(2):228\u201335. https:\/\/doi.org\/10.1002\/cpt.1833","journal-title":"Clin Pharmacol Ther"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s11096-016-0285-6","volume":"38","author":"Kim S. J. Lao","year":"2016","unstructured":"Lao KSJ, Chui CSL, Man KKC, Lau WCY, Chan EW, Wong ICK. Medication safety research by observational study design. Int J Clin Pharm. Published online March 22, 2016. Accessed August 8, 2024. https:\/\/doi.org\/10.1007\/s11096-016-0285-6","journal-title":"Int J Clin Pharm"},{"key":"836_CR11","unstructured":"European Medicines Agency. Post-authorization Safety Study Evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder: EUPAS16282. 2019. Accessed October 16, 2024. https:\/\/catalogues.ema.europa.eu\/sites\/default\/files\/document_files\/178-cl-114-clgr-disc01-en-final-02.pdf"},{"issue":"2","key":"836_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1574884708666131111211802","volume":"9","author":"V Abbing-Karahagopian","year":"2014","unstructured":"Abbing-Karahagopian V, Kurz X, Vries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol. 2014;9(2):130\u20138. https:\/\/doi.org\/10.2174\/1574884708666131111211802","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"836_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/kwt010","volume":"178","author":"D Madigan","year":"2013","unstructured":"Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645\u201351. https:\/\/doi.org\/10.1093\/aje\/kwt010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"836_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s43441-021-00342-4","volume":"56","author":"NE Storm","year":"2022","unstructured":"Storm NE, Chang W, Lin TC, et al. A novel case study of the use of Real-World evidence to support the registration of an osteoporosis product in China. Ther Innov Regul Sci. 2022;56(1):137\u201344. https:\/\/doi.org\/10.1007\/s43441-021-00342-4","journal-title":"Ther Innov Regul Sci"},{"issue":"27","key":"836_CR15","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1073\/pnas.1510502113","volume":"113","author":"G Hripcsak","year":"2016","unstructured":"Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci. 2016;113(27):7329\u201336. https:\/\/doi.org\/10.1073\/pnas.1510502113","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"836_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","volume":"19","author":"JM Overhage","year":"2012","unstructured":"Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inf Assoc JAMIA. 2012;19(1):54\u201360. https:\/\/doi.org\/10.1136\/amiajnl-2011-000376","journal-title":"J Am Med Inf Assoc JAMIA"},{"issue":"4","key":"836_CR17","doi-asserted-by":"publisher","first-page":"e15199","DOI":"10.2196\/15199","volume":"7","author":"ER Pfaff","year":"2019","unstructured":"Pfaff ER, Champion J, Bradford RL, et al. Fast healthcare interoperability resources (FHIR) as a Meta model to integrate common data models: development of a tool and quantitative validation study. JMIR Med Inf. 2019;7(4):e15199. https:\/\/doi.org\/10.2196\/15199","journal-title":"JMIR Med Inf"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"B8","DOI":"10.1016\/j.vaccine.2020.01.100","volume":"38","author":"M Sturkenboom","year":"2020","unstructured":"Sturkenboom M, Braeye T, Van Der Aa L, et al. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. Vaccine. 2020;38:B8\u201321. https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.100","journal-title":"Vaccine"},{"key":"836_CR19","doi-asserted-by":"publisher","unstructured":"Raventos B, Prieto-Alhambra D. Real-world evidence for regulatory purposes: the example of DARWIN EU\u00ae. Farm Hosp Organo Expresion Cient Soc Esp Farm Hosp. 2025;49(2):62\u20134. https:\/\/doi.org\/10.1016\/j.farma.2025.02.011.","DOI":"10.1016\/j.farma.2025.02.011"},{"issue":"S1","key":"836_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.2343","volume":"21","author":"R Platt","year":"2012","unstructured":"Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and drug administration\u2019s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(S1):1\u20138. https:\/\/doi.org\/10.1002\/pds.2343","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3233\/978-1-61499-921-8-60","volume":"255","author":"H Liyanage","year":"2018","unstructured":"Liyanage H, Liaw ST, Jonnagaddala J, Hinton W, de Lusignan S. Common data models (CDMs) to enhance international big data analytics: A diabetes use case to compare three CDMs. Stud Health Technol Inf. 2018;255:60\u20134. https:\/\/doi.org\/10.3233\/978-1-61499-921-8-60","journal-title":"Stud Health Technol Inf"},{"issue":"1","key":"836_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40264-017-0589-z","volume":"41","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhou X, Gao S, et al. Evaluation of electronic healthcare databases for Post-Marketing drug safety surveillance and pharmacoepidemiology in China. Drug Saf. 2018;41(1):125\u201337. https:\/\/doi.org\/10.1007\/s40264-017-0589-z","journal-title":"Drug Saf"},{"issue":"12","key":"836_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"KB Filion","year":"2016","unstructured":"Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of Incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1506115","journal-title":"N Engl J Med"},{"issue":"9","key":"836_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/pds.3440","volume":"22","author":"N Pratt","year":"2013","unstructured":"Pratt N, Andersen M, Bergman U, et al. Multi-country rapid adverse drug event assessment: the Asian pharmacoepidemiology network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22(9):915\u201324. https:\/\/doi.org\/10.1002\/pds.3440","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"836_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0895-4356(00)00259-6","volume":"53","author":"DA McKenzie","year":"2000","unstructured":"McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents. J Clin Epidemiol. 2000;53(12):1248\u201357. https:\/\/doi.org\/10.1016\/S0895-4356(00)00259-6","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"836_CR26","doi-asserted-by":"publisher","first-page":"e070985","DOI":"10.1136\/bmjopen-2022-070985","volume":"13","author":"E Eworuke","year":"2023","unstructured":"Eworuke E, Shinde M, Hou L, et al. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the Nitrosamine recalls: a descriptive cohort study. BMJ Open. 2023;13(4):e070985. https:\/\/doi.org\/10.1136\/bmjopen-2022-070985","journal-title":"BMJ Open"},{"issue":"6","key":"836_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/pds.3197","volume":"21","author":"PM Coloma","year":"2012","unstructured":"Coloma PM, Trifir\u00f2 G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21(6):611\u201321. https:\/\/doi.org\/10.1002\/pds.3197","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"836_CR28","doi-asserted-by":"publisher","first-page":"e028139","DOI":"10.1136\/bmjopen-2018-028139","volume":"9","author":"MK Bakker","year":"2019","unstructured":"Bakker MK, Bergman JEH, Krikov S, et al. Prenatal diagnosis and prevalence of critical congenital heart defects: an international retrospective cohort study. BMJ Open. 2019;9(7):e028139. https:\/\/doi.org\/10.1136\/bmjopen-2018-028139","journal-title":"BMJ Open"},{"issue":"1","key":"836_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cpt.2400","volume":"111","author":"K Joshua Lin","year":"2022","unstructured":"Joshua Lin K, Jin Y, Gagne J, et al. Longitudinal data discontinuity in electronic health records and consequences for medication effectiveness studies. Clin Pharmacol Ther. 2022;111(1):243\u201351. https:\/\/doi.org\/10.1002\/cpt.2400","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"836_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cpt.2560","volume":"112","author":"G Sarri","year":"2022","unstructured":"Sarri G, Bennett D, Debray T, et al. ISPE-Endorsed guidance in using electronic health records for comparative effectiveness research in COVID\u201019: opportunities and Trade\u2010Offs. Clin Pharmacol Ther. 2022;112(5):990\u20139. https:\/\/doi.org\/10.1002\/cpt.2560","journal-title":"Clin Pharmacol Ther"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/CLEP.S448980","volume":"16","author":"V Lo Re Iii","year":"2024","unstructured":"Lo Re Iii V, Cocoros N, Hubbard R, et al. Risk of arterial and venous thrombotic events among patients with COVID-19: A Multi-National collaboration of regulatory agencies from canada, europe, and united States. Clin Epidemiol. 2024;16:71\u201389. https:\/\/doi.org\/10.2147\/CLEP.S448980","journal-title":"Clin Epidemiol"},{"issue":"Supplement 8Sup","key":"836_CR32","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/MLR.0b013e31829b1bb1","volume":"51","author":"S Toh","year":"2013","unstructured":"Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013;51(Supplement 8Suppl 3):S4\u201310. https:\/\/doi.org\/10.1097\/MLR.0b013e31829b1bb1","journal-title":"Med Care"},{"key":"836_CR33","unstructured":"ICH M14 Draft Guideline. General Principles on Plan, Design and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines. 2024. Accessed October 16, 2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M14_Step3_DraftGuideline_2024_0521.pdf"}],"updated-by":[{"DOI":"10.1007\/s43441-025-00858-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000}}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00836-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:17:56Z","timestamp":1762028276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00836-5","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43441-025-00858-z","URL":"https:\/\/doi.org\/10.1007\/s43441-025-00858-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}